Electron Transport Chain: Complex I and II

Complex I, or NADH-Q oxidoreductase, is the largest enzyme complex in the electron transport chain, containing 45 subunits. It transfers electrons from NADH to coenzyme Q through key catalytic components including an NADH-binding site, FMN as the primary electron acceptor, and multiple iron-sulfur clusters. This initiates the energetically downhill electron transfer sequence.

Complex II, or succinate-Q reductase, is a nuclear-encoded tetramer with two hydrophilic subunits and two hydrophobic membrane proteins. Unlike Complex I, it participates in both the citric acid cycle and electron transport chain, transferring electrons from succinate through FADH2 to coenzyme Q via iron-sulfur clusters.

Complex I contains three major catalytic components: an NADH-binding site where high-energy electrons enter, FMN (flavin mononucleotide) as the primary electron acceptor, and multiple iron-sulfur clusters that facilitate electron transfer. These components work together to transfer electrons from NADH to coenzyme Q in a controlled, stepwise manner.

Complex I generates superoxide radicals during the large electron flow in oxidative phosphorylation. In healthy cells, ROS production is regulated at moderate levels necessary for normal cellular signaling. However, cancer cells with altered redox environments maintain elevated ROS production that triggers pro-tumorigenic pathways while exceeding normal antioxidant capacity.

Although rare, mutations in Complex II can lead to tumors of the carotid body, a sensory organ in the peripheral nervous system. Additionally, defects in Complex II have been linked to Huntington's disease. These mutations disrupt normal electron transport and cellular energy production, contributing to disease pathology.

In Parkinson's disease, there is a lack of function of Complex I, disrupting normal electron transport and ATP production in neurons. This mitochondrial dysfunction contributes to neurodegeneration. Complex I inhibitors like metformin can also induce programmed cell death in cancer cells by blocking respiratory functions.

ETC inhibitors like metformin, resveratrol, and fenretinide disrupt electron flow and trigger elevated ROS production. Cancer cells, with their altered redox environment and high antioxidant capacity, become more sensitive to ROS level alterations than normal cells. When ROS exceeds their scavenging capacity, cancer cells undergo programmed cell death.